Market Overview

GW Pharmaceutical's Upcoming Epidiolex Data Has Relatively Low Bar for Success

Share:

On Tuesday, Leerink reiterated an Outperform rating on GW Pharmaceuticals (NASDAQ: GWPH) and $79 price target.

Analyst Joseph Schwartz believes the “bar for success is relatively low” for upcoming Epidiolex data, based on the review of epilepsy trials. Schwartz went on to explain that 20 to 50 percent reduction in seizures versus placebo is generally good enough to approve add-on treatments.

In the second half of 2014, the company will start placebo-controlled proof-of-concept study followed by studies in Dravet and Lennox-Gastaut syndrome in 2015.

Shares closed up 1.5 percent to $66.19 in Tuesday's trading.

Latest Ratings for GWPH

DateFirmActionFromTo
May 2019ReiteratesOverweight
May 2019MaintainsOverweightOverweight
May 2019UpgradesPerformOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Joseph Schwartz LeerinkAnalyst Color Reiteration Analyst Ratings

 

Related Articles (GWPH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SKXMaintains44.0
HYMaintains66.0
MSFTMaintains160.0
SKXUpgrades
WLTWMaintains208.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

#PreMarket Primer: Wednesday, March 26: Markets Recover On Positive US Data

UPDATE: UBS Downgrades Navistar International Corporation to Neutral, Lowers PT to $36.00